Product information and disease descriptionProduct descriptionProduct informationDosing and administration
Dosage
13 evidence topics · 11 sources
Proposed labeled dose, titration, and dose modification
No evidence found.
Subcutaneous formulation: maintenance doses in the VANQUISH phase 3 trials
Subcutaneous formulation: titration schedule in the VANQUISH phase 3 trials
Subcutaneous formulation: rationale for the 1.25 mg starting dose
“Given that the 5 mg dose had a higher GI TEAE rate than the 10 mg dose, there does not seem to be a dose‐dependent increase in GI TEAEs if a 2.5 mg starting dose is used at the beginning of the titration phase. The clear benefit of starting below 5.0 mg and titrating up has informed the phase 3 trial design to further improve tolerability.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Subcutaneous formulation: doses and titration in the phase 2 trial
“Participants who met eligibility criteria were randomized to one of four VK2735 weekly subcutaneous injection treatment groups (2.5, 5.0, 10, or 15 mg) or the matched placebo injection group in a 1:1:1:1:1 ratio on day 1” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote